Griffiths, E. A., Srivastava, P., Gomez, E. C., Matsuzaki, J., Odunsi, K., Dillon, L. W., . . . Nemeth, M. J. Checkpoint immunotherapy is associated with preferential activation of tumor antigen–specific CD4+ T cells in MDS. Elsevier.
Chicago Style (17th ed.) CitationGriffiths, Elizabeth A., et al. Checkpoint Immunotherapy Is Associated with Preferential Activation of Tumor Antigen–specific CD4+ T Cells in MDS. Elsevier.
MLA (9th ed.) CitationGriffiths, Elizabeth A., et al. Checkpoint Immunotherapy Is Associated with Preferential Activation of Tumor Antigen–specific CD4+ T Cells in MDS. Elsevier.
Warning: These citations may not always be 100% accurate.